Cost-effectiveness of antenatal anti-D prophylaxis.
Health Econ
; 5(4): 319-28, 1996.
Article
em En
| MEDLINE
| ID: mdl-8880168
ABSTRACT
This paper estimates the incremental cost-effectiveness of providing antenatal anti-D prophylaxis in varying dose sizes to either primigravidae or all Rh D negative women. It presents a model for calculating the net cost per 1000 'at risk' women based on the costs of anti-D prophylaxis and the future NHS costs avoided. Incremental cost-effectiveness is measured in terms of the net cost per Rh D-alloimmunization and the net cost per Rh HD loss prevented. Programmes for Rh D negative primigravidae are more cost-effective than the same dose protocol extended to all Rh D negative women. The 1 x 1250 iu programme is the most cost-effective option.
Buscar no Google
Coleções:
01-internacional
Base de dados:
MEDLINE
Assunto principal:
Cuidado Pré-Natal
/
Custos de Cuidados de Saúde
/
Imunoglobulina rho(D)
/
Eritroblastose Fetal
Tipo de estudo:
Etiology_studies
/
Health_economic_evaluation
/
Incidence_studies
/
Observational_studies
/
Prognostic_studies
/
Risk_factors_studies
Limite:
Female
/
Humans
/
Newborn
/
Pregnancy
País/Região como assunto:
Europa
Idioma:
En
Ano de publicação:
1996
Tipo de documento:
Article